In a retrospective study [92], Tg-DT alone did not prove to be an independent survival predictor in all patients with progressive DTC (especially not in patients with only minor lymphogenic metastasis); however, when focusing on patients with a high tumor burden (Tg > 100 ng/mL), significant differences in survival rates were found when the Tg-DT was classified into the three groups of < 3 months, 3–12 months and >12 months. Here, TG is linked to neoplasm.